[go: up one dir, main page]

DE69326937D1 - Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung - Google Patents

Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung

Info

Publication number
DE69326937D1
DE69326937D1 DE69326937T DE69326937T DE69326937D1 DE 69326937 D1 DE69326937 D1 DE 69326937D1 DE 69326937 T DE69326937 T DE 69326937T DE 69326937 T DE69326937 T DE 69326937T DE 69326937 D1 DE69326937 D1 DE 69326937D1
Authority
DE
Germany
Prior art keywords
combination
hormonal
binding molecules
cancer treatment
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69326937T
Other languages
English (en)
Other versions
DE69326937T2 (de
Inventor
Beatrice C Langton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare Pharmaceuticals Inc
Original Assignee
Berlex Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69326937(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Berlex Biosciences Inc filed Critical Berlex Biosciences Inc
Publication of DE69326937D1 publication Critical patent/DE69326937D1/de
Application granted granted Critical
Publication of DE69326937T2 publication Critical patent/DE69326937T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69326937T 1993-03-24 1993-03-24 Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung Expired - Fee Related DE69326937T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93250090A EP0616812B1 (de) 1993-03-24 1993-03-24 Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung

Publications (2)

Publication Number Publication Date
DE69326937D1 true DE69326937D1 (de) 1999-12-09
DE69326937T2 DE69326937T2 (de) 2000-12-28

Family

ID=8214259

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326937T Expired - Fee Related DE69326937T2 (de) 1993-03-24 1993-03-24 Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung

Country Status (7)

Country Link
EP (1) EP0616812B1 (de)
AT (1) ATE186219T1 (de)
DE (1) DE69326937T2 (de)
DK (1) DK0616812T3 (de)
ES (1) ES2141128T3 (de)
GR (1) GR3032511T3 (de)
PT (1) PT616812E (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP2014770A3 (de) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1-induziertes sekretiertes Polypeptid WISP-2
ATE409225T1 (de) 1997-10-29 2008-10-15 Genentech Inc Durch wnt-1 induzierbare gene
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2288649T3 (es) 1997-11-21 2008-01-16 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
EP1947119A3 (de) 1997-12-12 2012-12-19 Genentech, Inc. Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
EP2075335A3 (de) 1998-12-22 2009-09-30 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
CN101518653B (zh) 1999-06-25 2015-08-19 基因技术股份有限公司 使用抗ErbB抗体-类美坦素偶联物的治疗方法
LT2803367T (lt) 1999-06-25 2018-03-26 Immunogen, Inc. Gydymo būdai, naudojant anti-erbb antikūno-maitanzinoido konjugatus
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20090024308A (ko) 1999-08-27 2009-03-06 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
EP1897945B1 (de) 1999-12-23 2012-01-18 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
CA2397207C (en) 2000-01-13 2013-12-03 Genentech, Inc. Novel stra6 polypeptides
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
PL400669A1 (pl) 2000-05-19 2012-11-05 Genentech, Inc. Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
EP2075253A1 (de) 2000-06-23 2009-07-01 Genentech, Inc. Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP2000545B1 (de) 2001-06-20 2011-08-31 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Lungentumoren
EP2174953A1 (de) 2001-09-18 2010-04-14 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
WO2003057160A2 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1575480A4 (de) 2002-02-22 2008-08-06 Genentech Inc Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
SI2289942T1 (sl) 2002-04-10 2013-11-29 Genentech, Inc. Variante protitelesa proti HER2
EP2011886A3 (de) 2002-04-16 2009-02-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
CA2486252C (en) 2002-06-07 2012-07-24 Genentech, Inc. Methods for screening for agents that modulate hepatocellular carcinoma development
AU2003247806B2 (en) 2002-07-08 2009-11-12 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2376165T3 (es) 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
EP2085096A3 (de) 2002-09-11 2009-08-12 Genentech, Inc. Neuartige Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
US20060281146A1 (en) 2002-09-11 2006-12-14 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1585482A4 (de) 2002-09-25 2009-09-09 Genentech Inc Neue zusammensetzungen und verfahren zur behandlung von psoriasis
CA2503330A1 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2364716A3 (de) 2002-11-08 2012-01-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen im Zusammenhang mit natürlichen Killerzellen
EP2179742A1 (de) 2002-11-26 2010-04-28 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP1608967A4 (de) 2003-04-01 2006-08-09 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
PT1641822E (pt) 2003-07-08 2013-08-27 Genentech Inc Polipéptidos heterólogos il-17 a/f e suas utilizações terapêuticas
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PT2161283E (pt) 2003-11-17 2014-08-29 Genentech Inc Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CA2563341C (en) 2004-04-08 2014-10-21 David B. Agus Erbb antagonists for pain therapy
EP2286844A3 (de) 2004-06-01 2012-08-22 Genentech, Inc. Antikörper-Arzneimittelkonjugate und Verfahren
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
DK1817055T3 (da) 2004-11-10 2013-04-08 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
JP2008528486A (ja) 2005-01-21 2008-07-31 ジェネンテック・インコーポレーテッド Ｈｅｒ抗体の一定投薬
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
BRPI0607985A2 (pt) 2005-03-10 2009-10-27 Genentech Inc modulador da dscr1, métodos de tratamento, método de melhoria de efeitos colaterais e método de inibição do crescimento de tumores
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
NZ712762A (en) 2005-12-02 2017-03-31 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2004221A2 (de) 2006-03-23 2008-12-24 Novartis Pharma AG Antitumorzellenantigen-antikörper-therapeutika
EP2082645A1 (de) 2006-04-19 2009-07-29 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
US8444971B2 (en) 2006-11-27 2013-05-21 Diadexus, Inc. OVR110 antibody compositions and methods of use
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US8088378B2 (en) 2007-07-16 2012-01-03 Genetech Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
MX2010008437A (es) 2008-01-31 2010-11-25 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
JP5770624B2 (ja) 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
HUE030092T2 (en) 2008-05-06 2017-05-29 Genentech Inc Affinity CRIg variants
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
CN102356092B (zh) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
RU2563359C2 (ru) 2009-11-30 2015-09-20 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
WO2011069104A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
RU2587619C2 (ru) 2010-02-18 2016-06-20 Дженентек, Инк. Антагонисты неурегулина и применение их в лечении злокачественного новообразования
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2013533732A (ja) 2010-05-03 2013-08-29 ジェネンテック， インコーポレイテッド 腫瘍の診断と治療のための組成物と方法
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
WO2012075581A1 (en) 2010-12-06 2012-06-14 Ym Biosciences Inc. Antibodies selective for cells presenting erbb2 at high density
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2013025853A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
EP2785864A2 (de) 2011-11-30 2014-10-08 F. Hoffmann-La Roche AG Erbb3-mutationen bei krebs
EP2788500A1 (de) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identifizierung von non-respondern auf her2-inhibitoren
EP2831115A1 (de) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnose und behandlungen im zusammenhang mit her3-hemmern
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CR20200550A (es) 2018-04-13 2020-12-15 Genentech Inc Formulaciones de inmunoconjugado anti-cd79b estables
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0444181T3 (da) * 1989-08-04 2002-02-25 Schering Ag C-erbB-2 eksternt domæne: gp75

Also Published As

Publication number Publication date
GR3032511T3 (en) 2000-05-31
ATE186219T1 (de) 1999-11-15
ES2141128T3 (es) 2000-03-16
EP0616812A1 (de) 1994-09-28
DE69326937T2 (de) 2000-12-28
EP0616812B1 (de) 1999-11-03
PT616812E (pt) 2000-04-28
DK0616812T3 (da) 2000-04-25

Similar Documents

Publication Publication Date Title
DE69326937D1 (de) Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
NO20061723L (no) Intercellulaert domene av HER-2/neu-protein for forhindring eller behandling av malignitet
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BRPI0213223B8 (pt) polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
ES2391382T8 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
DE60230807D1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
IL112963A0 (en) A pharmaceutical composition containing gamma globulins or fragments thereof
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee